Johnson & Johnson (JNJ) announced last night its decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as ...
The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...
Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...
This report covers significant developments in the health sector, including Johnson & Johnson halting a depression drug trial ...
Johnson & Johnson (NYSE:JNJ) has decided to discontinue a Phase 3 program for its depression therapy aticaprant due to insufficient efficacy, the pharma giant announced. Known as VENTURA ...
Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an ...
J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.